The National Human Genome Research Institute, NHGRI, invited Karam Diaby, Ph.D., an assistant professor of pharmaceutical outcomes and policy in the University of Florida College of Pharmacy, to participate in a panel discussion shaping the organization’s strategic plan. The strategic planning workshop was held in Bethesda, Maryland, and will help NHGRI establish a “2020 vision for genomics” and culminate in the publication of a new NHGRI strategic plan in October.
Diaby was invited to the panel to provide a health economic perspective on genomic medicine. His research assesses the value of new health care intervention technology, including pharmacogenomics testing. Diaby serves as a co-investigator on an NIH grant where he offers analysis of the cost-effectiveness of genotype-guided approaches to pain and the selection of antidepressants. On another grant, he is assessing the cost-effectiveness of rapid whole genome sequencing compared to its omission in critically ill pediatric patients.